Table 1

Characteristics of the breast cancer cases and controls

Variable
Cases (n = 648)
Controls (n = 659)
P diffa

Age at blood draw (years; mean ± SD)
69.2 (5.8)
69.3 (5.76)
P = 0.93
Age at diagnosis (years; mean ± SD)
68.9 (6.25)
-
-
BMI (kg/m2; mean ± SD)
25.2 (4.54)
25.5 (4.56)
P = 0.22
Adult weight change (lb; mean ± SD)
27.9 (25.65)
27.1 (25.91)
P = 0.58
Race (n [%])



     White
642 (99.1)
653 (99.1)
P = 0.98
     Other
6 (0.9)
6 (0.9)

BMI (kg/m2; n [%])



     <25
364 (56.2)
338 (51.3)
P = 0.16
     25–30
170 (26.2)
210 (31.9)

     30+
106 (16.4)
103 (15.6)

     Missing
8 (1.2)
8 (1.2)

History of breast cysts (n [%])



     No
402 (62)
460 (69.8)
P = 0.003
     Yes
246 (38)
199 (30.2)

Postmenopausal hormone use (n [%])



     Never
213 (32.9)
255 (38.7)
P < 0.0001
     ERT
204 (31.5)
260 (39.5)

     CHRT
203 (31.3)
120 (18.2)

     Unknown
28 (4.3)
24 (3.6)

Family history of breast cancer (n [%])



     No
513 (79.2)
564 (85.6)
P = 0.002
     Yes
135 (20.8)
95 (14.4)

Education (n [%])



     <High school
7 (1.1)
25 (3.8)
P = 0.0008
     High school
166 (25.6)
196 (29.7)

     Some college
181 (27.9)
190 (28.8)

     College +
294 (45.4)
248 (37.6)

Age at menopause (years; n [%])



     <40
55 (8.5)
72 (10.9)
P = 0.002
     40 to 44
65 (10)
85 (12.9)

     45 to 49
139 (21.5)
179 (27.2)

     50 to 54
301 (46.5)
258 (39.2)

     55+
88 (13.6)
65 (9.9)


aP value is a t-test for the means, and a Pearson χ2 for the frequencies. BMI, body mass index; CHRT, combined hormone replacement therapy; ERT, estrogen replacement therapy; SD, standard deviation.

Feigelson et al. Breast Cancer Research 2008 10:R57   doi:10.1186/bcr2114

Open Data